Laurus Labs Share Price

Overview
Recos
News
Analysis
Financials
Forecast
Technicals
Peers
Shareholdings
MF
F&O
Corp Actions
About

Laurus Labs Share Price

1,390.805.10 (0.37%)

Closed
As On: 11 Jun, 2026, 03:52 PM IST
As On: 11 Jun, 2026, 03:40 PM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Try ETMarkets GPTNEW

Open	1,385.00
High	1,408.90
Low	1,376.60
Prev Close	1,385.70
Volume	15,05,571
VWAP(₹)	1,396.66

Key Metrics

PE Ratio(x)	84.48
EPS - TTM(₹)	16.46
MCap(₹ Cr.)	75,083.25
MCap Rank	10
PB Ratio(x)	13.77
Div Yield(%)	0.14
Face Value(₹)	2.00
52W High(₹)	1,457.00
52W Low(₹)	641.05
MCap/Sales	7.86
Beta(1 Month)	1.11
BV/Share(₹)	100.61

Laurus Labs share price insights

Rank 376 - ET 5002025 ranking

Intraday fact check
In the last 9 years, only 1.45 % trading sessions saw intraday declines higher than 5 % .
Beating 3 Yr Revenue CAGR
Company's annual revenue growth of 22.22% outperformed its 3 year CAGR of 4.26%. (Source: Consolidated Financials)
Employee & Interest Expense
Company has spent 2.41% of its operating revenues towards interest expenses and 13.14% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)
Laurus Labs Share Price Update
Laurus Labs Ltd. share price moved up by 0.37% from its previous close of Rs 1,385.70. Laurus Labs Ltd. stock last traded price is 1,390.80
Share Price Value
Today/Current/Last 1,390.801,393.00
Previous Day 1,385.701,385.05

Found Insights useful?

Laurus Labs Share Price Returns

1 Day	0.37%
1 Month	9.79%
3 Months	33.6%
1 Year	105.6%
3 Years	308.46%
5 Years	127.44%

Laurus Labs Share Recommendations

Mean recosCurrent

HOLD

13 Analysts

Strong
SellSellHoldBuyStrong
Buy

Analyst Trends

Ratings	Current	1W Ago	1M Ago	3M Ago
Strong Buy	2	2	2	2
Buy	3	3	3	3
Hold	3	3	3	3
Sell	3	3	3	4
Strong Sell	2	2	2	2
# Analysts	13	13	13	14

Recent Recos

Target₹710
Organizationothers
BUY

Target₹480
OrganizationMotilal Oswal Financial Services
BUY

Target₹338.8
OrganizationICICI Direct
BUY

View all Stock Recommendations

News & Analysis

View all Laurus Labs Share News & Announcements

Financials

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	1,823.37	1,784.05	1,680.43	1,580.00	1,778.87
Total Income Growth (%)	2.20	6.17	6.36	-11.18	24.88
Total Expenses	1,421.56	1,418.70	1,370.70	1,304.28	1,410.13
Total Expenses Growth (%)	0.20	3.50	5.09	-7.51	14.09
EBIT	401.81	365.35	309.73	275.72	368.74
EBIT Growth (%)	9.98	17.96	12.33	-25.23	95.64
Profit after Tax (PAT)	279.14	251.66	194.97	163.02	233.67
PAT Growth (%)	10.92	29.08	19.60	-30.23	153.16
EBIT Margin (%)	22.04	20.48	18.43	17.45	20.73
Net Profit Margin (%)	15.31	14.11	11.60	10.32	13.14
Basic EPS (₹)	5.17	4.67	3.61	3.02	4.34

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	1,593.39	1,523.79	1,595.05	1,454.27	1,722.17
Total Income Growth (%)	4.57	-4.47	9.68	-15.56	35.36
Total Expenses	1,300.11	1,257.87	1,272.53	1,198.94	1,343.36
Total Expenses Growth (%)	3.36	-1.15	6.14	-10.75	17.06
EBIT	293.28	265.92	322.52	255.33	378.81
EBIT Growth (%)	10.29	-17.55	26.31	-32.60	203.68
Profit after Tax (PAT)	191.79	175.08	215.67	157.94	251.90
PAT Growth (%)	9.54	-18.82	36.55	-37.30	339.85
EBIT Margin (%)	18.41	17.45	20.22	17.56	22.00
Net Profit Margin (%)	12.04	11.49	13.52	10.86	14.63
Basic EPS (₹)	3.55	3.25	3.99	2.93	4.68

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	6,861.28	5,613.89	5,067.17	6,046.55	4,949.15
Total Revenue Growth (%)	22.22	10.79	-16.20	22.17	2.31
Total Expenses	5,679.40	5,129.60	4,830.81	4,937.61	3,865.30
Total Expenses Growth (%)	10.72	6.19	-2.16	27.74	9.31
Profit after Tax (PAT)	888.79	358.32	160.55	790.11	827.52
PAT Growth (%)	148.04	123.18	-79.68	-4.52	-15.87
Operating Profit Margin (%)	19.75	12.33	8.31	21.09	23.99
Net Profit Margin (%)	13.04	6.45	3.18	13.08	16.76
Basic EPS (₹)	16.47	6.65	2.98	14.69	15.42

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	6,119.93	5,282.08	4,859.81	5,789.40	4,720.52
Total Revenue Growth (%)	15.86	8.69	-16.06	22.64	-1.57
Total Expenses	5,125.84	4,778.27	4,558.34	4,737.97	3,745.11
Total Expenses Growth (%)	7.27	4.82	-3.79	26.51	6.35
Profit after Tax (PAT)	740.48	380.39	223.70	760.38	750.09
PAT Growth (%)	94.66	70.04	-70.58	1.37	-21.55
Operating Profit Margin (%)	17.90	12.47	9.39	20.73	22.58
Net Profit Margin (%)	12.16	7.29	4.64	13.17	15.93
Basic EPS (₹)	13.72	7.06	4.15	14.14	13.97

All figures in Rs Cr, unless mentioned otherwise

Insights

Beating 3 Yr Revenue CAGR
Company's annual revenue growth of 22.22% outperformed its 3 year CAGR of 4.26%. (Source: Consolidated Financials)
Employee & Interest Expense
Company has spent 2.41% of its operating revenues towards interest expenses and 13.14% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	10,511.19	9,335.57	8,387.03	7,660.40	6,968.04
Total Assets Growth (%)	12.59	11.31	9.49	9.94	21.17
Total Liabilities	5,079.83	4,733.11	4,271.46	3,611.74	3,608.99
Total Liabilities Growth (%)	7.33	10.81	18.27	0.08	14.57
Total Equity	5,431.36	4,602.46	4,115.57	4,048.66	3,359.05
Total Equity Growth (%)	18.01	11.83	1.65	20.53	29.16
Current Ratio (x)	1.33	1.22	1.23	1.42	1.25
Total Debt to Equity (x)	0.45	0.60	0.61	0.49	0.52
Contingent Liabilities	863.38	670.40	414.14	494.88	481.87

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	9,540.03	8,586.75	7,667.48	6,957.96	6,608.53
Total Assets Growth (%)	11.10	11.99	10.20	5.29	17.48
Total Liabilities	4,288.09	4,022.80	3,460.43	2,901.14	3,220.32
Total Liabilities Growth (%)	6.59	16.25	19.28	-9.91	10.55
Total Equity	5,251.94	4,563.95	4,207.05	4,056.82	3,388.21
Total Equity Growth (%)	15.07	8.48	3.70	19.73	24.92
Current Ratio (x)	1.34	1.27	1.29	1.51	1.32
Total Debt to Equity (x)	0.38	0.51	0.49	0.41	0.48
Contingent Liabilities	1,306.14	1,093.33	887.54	677.17	475.95

All figures in Rs Cr, unless mentioned otherwise

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	1,623.50	601.65	665.69	993.90	911.10
Net Cash used in Investing Activities	-1,088.66	-681.72	-822.42	-996.06	-914.34
Net Cash flow from Financing Activities	-524.72	39.28	249.83	-26.64	30.26
Net Cash Flow	13.12	-39.40	93.27	-29.68	26.89
Closing Cash & Cash Equivalent	112.66	99.54	138.94	45.67	75.35
Closing Cash & Cash Equivalent Growth (%)	13.18	-28.36	204.23	-39.39	55.49
Total Debt/ CFO (x)	1.48	4.48	3.77	1.98	1.90

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	1,384.95	540.06	658.54	881.55	822.97
Net Cash used in Investing Activities	-847.06	-591.65	-756.74	-735.27	-836.61
Net Cash flow from Financing Activities	-550.74	59.32	139.41	-185.19	15.19
Net Cash Flow	-12.85	7.73	41.21	-38.91	1.55
Closing Cash & Cash Equivalent	37.51	50.36	42.63	1.42	40.33
Closing Cash & Cash Equivalent Growth (%)	-25.52	18.13	2,902.11	-96.48	4.00
Total Debt/ CFO (x)	1.44	4.30	3.11	1.91	1.97

All figures in Rs Cr, unless mentioned otherwise

Insights

Increase in Cash from Investing
Company has used Rs 1088.66 cr for investing activities which is an YoY increase of 59.69%. (Source: Consolidated Financials)

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	16.76	8.01	3.90	19.56	24.69
Return on Capital Employed (%)	19.57	11.82	7.94	24.37	27.63
Return on Assets (%)	8.45	3.83	1.91	10.31	11.87
Interest Coverage Ratio (x)	11.12	5.55	4.39	9.68	14.26
Asset Turnover Ratio (x)	0.69	0.63	0.63	0.83	0.76
Price to Earnings (x)	60.61	92.59	131.58	20.00	38.46
Price to Book (x)	10.10	7.40	5.14	3.91	9.46
EV/EBITDA (x)	30.64	32.07	29.21	11.09	23.24
EBITDA Margin (%)	26.80	20.07	15.94	26.45	29.09

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	14.09	8.33	5.31	18.74	22.13
Return on Capital Employed (%)	17.35	11.99	9.17	24.67	25.46
Return on Assets (%)	7.76	4.42	2.91	10.92	11.35
Interest Coverage Ratio (x)	15.24	6.87	5.29	10.28	14.79
Asset Turnover Ratio (x)	0.67	0.64	0.66	0.85	0.77
Price to Earnings (x)	72.46	87.72	95.24	20.79	42.37
Price to Book (x)	10.20	7.25	5.02	3.89	9.36
EV/EBITDA (x)	37.78	35.04	29.00	11.66	25.63
EBITDA Margin (%)	24.12	19.34	16.56	25.94	27.59

Found Financials useful?

Share Price Forecast

Exclusively for ETPrime

REVENUE
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP
EARNINGS
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP
PRICE
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP

Technicals

Buy/Sell Signals
Stochastic Crossover
Bearish signal on weekly chart
Appeared on: 5 Jun 2026
Region: Overbought (Above 80)
Last Signal 8 May 2026 (Loss -0.56%)
Average price decline of -6.41% within 7 weeks of Bearish signal in last 10 years
Price Analysis
46%
Positive Movement
since 1st Jan 2005
on basis
54%
Negative Movement
since 1st Jan 2005
on basis
Exclude
Global Meltdown1st Jan 2008 to 10th Nov 2008
Covid Crisis1st Feb 2020 to 31st Mar 2020
Pivot Levels
R1 1414.97 Pivot
1397.73
S1 1368.47
R2 1444.23 S2 1351.23
R3 1490.73 S3 1304.73
Average True Range
5 Days 14 Days 28 Days
39.67 35.37 34.56

Found Technicals useful?

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Laurus Labs	84.48	13.82	16.76	19.57	8.45	4.26	19.75	13.06	16.47	1.33	0.45	1.48
Aurobindo Pharma	22.78	2.24	9.24	13.73	5.99	10.62	16.52	10.40	60.34	1.81	0.20	1.39
Biocon	174.85	1.84	1.13	3.71	0.60	14.20	10.87	2.17	2.82	1.22	0.44	7.43
Alkem Labs	27.54	4.42	16.65	19.92	11.02	8.89	21.79	15.99	192.51	2.55	0.12	0.83
Glenmark Pharma	44.44	5.76	12.95	32.95	6.84	9.34	26.25	8.01	48.26	1.77	0.00	0.00
Add More

Annual Ratios (%)

Choose from Peers

Ipca Labs
Ajanta Pharma
Gland Pharma
J B Chemicals
Piramal Pharma

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

Found Peer Comparison useful?

Shareholding Pattern

Total Shareholdings

Category	No. of Shares	Percentage	% Change QoQ
Promoters	14,84,31,720	27.49 %	0.00
Pledge	40,00,000	2.69 %	0.00
FII	13,94,07,674	25.82 %	-0.69
DII	7,54,00,739	13.96 %	1.54
MF	6,05,94,237	11.22 %	1.73
Others	17,66,16,449	32.72 %	-0.84

QoQ Change
Category Mar 2026 Dec 2025 Sep 2025 Jun 2025
Promoters 27.49 27.49 27.59 27.59
Pledge 2.69 2.69 2.69 2.69
FII 25.82 26.52 26.17 25.70
DII 13.96 12.42 11.71 11.93
Mutual Funds 11.22 9.49 8.53 7.78
Others 32.72 33.57 34.53 34.78

Mutual Funds Ownership

MF Ownership as on 30 April 2026

Mirae Asset Large & Midcap Direct-G
Equity: Large & MidCap
2
- 1,027.63
  Amount Invested (in Cr.)
- 2.42721563%
  % of AUM
- 0.00
  % Change (MoM basis)
Mirae Asset ELSS Tax Saver Direct-G
Equity: ELSS
3
- 785.45
  Amount Invested (in Cr.)
- 3.10864419%
  % of AUM
- 0.00
  % Change (MoM basis)
Mirae Asset Midcap Direct-G
Equity: Mid Cap
3
- 530.29
  Amount Invested (in Cr.)
- 2.8839209%
  % of AUM
- 7.78
  % Change (MoM basis)

View all Mutual Fund Schemes

Laurus Labs Top Searches

Corporate Actions

Recent
Board Meeting
Quarterly Results
Jan 09, 2026
Interim Dividend
40%
Oct 23, 2025
Board Meeting
Quarterly Results & Interim Dividend
Oct 09, 2025

Announced on	Meeting on
Jan 09, 2026	Jan 23, 2026
Quarterly Results
Oct 09, 2025	Oct 23, 2025
Quarterly Results & Interim Dividend
Jul 09, 2025	Jul 25, 2025
Quarterly Results
Apr 11, 2025	Apr 24, 2025
Audited Results & Interim Dividend
Jan 06, 2025	Jan 24, 2025
Quarterly Results

Dividends
Announced on Ex-Date Dividend%
Oct 23, 2025 Oct 31, 2025 40%
Apr 24, 2025 May 09, 2025 40%
Oct 24, 2024 Nov 06, 2024 20%
Apr 25, 2024 May 08, 2024 20%
Oct 20, 2023 Nov 02, 2023 20%
Bonus
No Data Available
Splits
Announced on Ex-Date
Apr 30, 2020 Sep 29, 2020
Split: Old FV10.0| New FV:2.0
Rights
No Data Available

AGM/EGM Meetings

Announced on	Meeting on
Jun 03, 2025	Jun 26, 2025
-
Sep 02, 2024	Oct 05, 2024
-
Apr 25, 2024	Jul 11, 2024
Book closure from Jul 5, 2024 to Jul 11, 2024
Apr 27, 2023	Jul 14, 2023
Book closure from Jul 8, 2023 to Jul 14, 2023
Feb 06, 2023	Mar 11, 2023
-

About Laurus Labs

Laurus Labs Ltd., incorporated in the year 2005, is a Mid Cap company (having a market cap of Rs 75,083.25 Crore) operating in Pharmaceuticals sector.

Laurus Labs Ltd. key Products/Revenue Segments include Pharmaceutical Products, Contract Service, Other Operating Revenue, Scrap for the year ending 31-Mar-2026.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 1,823.37 Crore, up 2.20 % from last quarter Total Income of Rs 1,784.05 Crore and up 2.50 % from last year same quarter Total Income of Rs 1,778.87 Crore. Company has reported net profit after tax of Rs 281.91 Crore in latest quarter.

The company’s top management includes Dr.Ravindranath Kancherla, Dr.Satyanarayana Chava, Mr.V V Ravi Kumar, Dr.C V Lakshmana Rao, Mr.Krishna Chaitanya Chava, Ms.Soumya Chava, Mrs.Aruna Rajendra Bhinge, Mr.Karnam Sekar, Dr.Rajesh Koshy Chandy, Mr.Ramesh Subrahmanian, Mr.G Venkateswar Reddy. Company has Deloitte Haskins & Sells LLP as its auditors. As on 31-03-2026, the company has a total of 53.99 Crore shares outstanding.

Laurus Labs Share Price Today is Rs. 1390.80. On previous day, the Laurus Labs Share Price (NSE) closed at Rs. 1424.4, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 27.49% of the stake in Laurus Labs shares, out of which 2.69% was pledged. On the same date, foreign institutional investors' (FII) holdings of Laurus Labs stocks was 25.82% as compared to 26.52% in Dec 2025 with decrease of 0.7%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 13.96% as compared to 12.42% in Dec 2025 with increase of 1.54%. Out of the total DII holdings in Laurus Labs shares 11.22% was held by mutual funds. The rest including public held is 32.73%. Laurus Labs stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Laurus Labs Dividend: Ever since 2005, Laurus Labs dividends has been paid out around 18 times. As on 11 Jun, 2026, 03:52 PM IST, The overall dividend yield for Laurus Labs stands at 0.09%. The last dividend paid was on May 8, 2026 (Rs. 1.2). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 16.46.

Laurus Labs Bonus: The most recent bonus issue had been in year null around 0 years ago at 0 : 0 ratio. The first bonus issue was announced in null.

Stock Forecast:
After showing 1823.37 Cr. of sales and 2.2% of quarterly net profit, there have been multiple ups and downs in the Laurus Labs stock prices in the past few weeks. For example, Laurus Labs stock price on 3rd of June 2026 was around Rs. 1394.3. Laurus Labs share price now stands at an average of Rs. 1390.80. Judging by last week's performance, stock is in up trend.

Laurus Labs has a median target price of Rs. 1060.54 in 12 months by 13 analysts. They have provided a high estimate of Rs. 1370.0 and low estimate of Rs. 730.0 for Laurus Labs share.

Historical Prices and Performance:
Laurus Labs, incorporated in 2005 is a Large Cap company (with a market cap of Rs. 74807.93) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Laurus Labs stock was 16.76%, 8.01%, 3.9%, 19.56% and 24.69% respectively.
The Laurus Labs share gave a 3 year return of 306.96% as compared to Nifty 50 which gave a return of 25.06%.
Laurus Labs announced 60.0% final dividend on May 8, 2026.

Key Metrics:
PE Ratio of Laurus Labs is 84.17
Prices/Sales Ratio of Laurus Labs is 7.86
Price/Book Ratio of Laurus Labs is 13.77

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Laurus Labs, major competitors and peers include Aurobindo Pharma, Biocon, Alkem Labs and Glenmark Pharma. As of Dec 2025, the dividend yield of Laurus Labs stands at 0.09% while Aurobindo Pharma, Biocon, Alkem Labs and Glenmark Pharma stand at 0.28%, 0.12%, 1.0% and 0.23% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 84.17 and 13.77 respectively.

Recommendations:
The current total number of analysts covering the stock stands at 13, Three months ago this number stood at 14. Out of total, 2 analyst have a'Strong Buy' reco, 3 analyst have a'Buy' reco, 3 analyst have a'Hold' reco, 3 analyst have a'Sell' reco.

Mean recommendations by 13 analyst stand at'Buy'.

Leadership of Laurus Labs :
G Venkateswar Reddy is Co. Secretary & Compl. Officer
Venkata Ramana Rao is Senior Vice President
Sita Ramaiah is Executive Vice President - Finance
Suryadevara Srinivasa Rao is Executive Vice President
Narasimha Rao Chava is Executive Vice President - HR
S Srinivasa Rao is President
Martyn Oliver James Peck is Executive Vice President
V Uma Maheswer Rao is President
Rajaram Iyer is Executive Vice President
Thomas Versosky is President
Arnaud Martin is Executive Vice President
Jyothi Basu Abbineni is Executive Vice President
Ravindranath Kancherla is Non Exe.Chairman&Ind.Director
V V Ravi Kumar is Executive Director & CFO
Satyanarayana Chava is Executive Director & CEO
Soumya Chava is Executive Director
C V Lakshmana Rao is Executive Director
Krishna Chaitanya Chava is Executive Director
Aruna Rajendra Bhinge is Ind. Non-Executive Director
Karnam Sekar is Ind. Non-Executive Director
Rajesh Koshy Chandy is Ind. Non-Executive Director
Ramesh Subrahmanian is Ind. Non-Executive Director

Show More

Industry

Pharma - Indian

Key Indices Listed On

Nifty Smallcap 100, Nifty 500, BSE 500, Nifty Pharma, Nifty Alpha 50

Address

Laurus Enclave, Plot Office 01,Edulapakabonangi Village,Vishakapatnam, Andhra Pradesh - 531021

Contact

secretarial@lauruslabs.com

https://www.lauruslabs.com

Executive Leadership

RK

Ravindranath Kancherla

Non Exe.Chairman&Ind.Director

SC

Satyanarayana Chava

Executive Director & CEO

VV

V V Ravi Kumar

Executive Director & CFO

CV

C V Lakshmana Rao

Executive Director

Show More

Auditors

Deloitte Haskins & Sells LLP

FAQs about Laurus Labs share

1. What's the Laurus Labs share price today?
Laurus Labs share price is Rs 1,390.80 as on 11 Jun, 2026, 03:52 PM IST. Laurus Labs share price is up by 0.37% based on previous share price of Rs 1,424.4. Laurus Labs share price trend:
- Last 12 Months: Laurus Labs share price moved up 105.60%
- Last 3 Years: Laurus Labs Share price moved up by 308.46%
2. What is the market cap of Laurus Labs?
Laurus Labs share has a market capitalization of Rs 75,083.25 Cr. Within Pharmaceuticals sector, it's market cap rank is 10.
3. What is the PE & PB ratio of Laurus Labs?
The PE ratio of Laurus Labs stands at 84.17, while the PB ratio is 16.24.
4. What is 52 week high/low of Laurus Labs share price?
Laurus Labs share price saw a 52 week high of Rs 1,457.00 and 52 week low of Rs 641.05.
5. What are the returns for Laurus Labs share?
Return Performance of Laurus Labs Shares:
- 1 Week: Laurus Labs share price moved down by 2.55%

Top Gainers

As on 03:59 PM | 11 Jun 2026

Aegis Logistics

925.90

124.90 (15.60%)

111.45

8.52 (8.28%)

DOMS Industries

2,255.40

136.81 (6.46%)

Blue Jet Healthcare

498.45

28.70 (6.11%)

1,923.80

90.80 (4.96%)

Top Losers

As on 03:59 PM | 11 Jun 2026

Balkrishna Ind.

1,974.00

-109.20 (-5.25%)

1,133.10

-60.31 (-5.06%)

155.70

-7.93 (-4.85%)

166.91

-8.00 (-4.57%)

Adani Transmission

1,466.70

-68.90 (-4.49%)

Equity Quick Links

Top Gainers
Top Losers
Hourly gainers
Hourly losers
Sensex
Nifty
NSE
BSE

Midcap stocks
Smallcap stocks
Largecap stocks
Sensex
Nifty
NSE
BSE
MCX Live

More from Markets

IPO
Stock market news
Budget 2022 Live Updates
Cryptocurrency
Currency converter
NSE holiday list

Trending in Markets

DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

By using this site, you agree to the Terms of Service and Privacy Policy.